1. Cell Mol Immunol. 2022 Sep;19(9):1054-1066. Epub 2022 Aug 12.
2. Adv Exp Med Biol. 2020:1231:79-96.
3.Oncoimmunology. 2022 Aug 29;11(1):2115655. eCollection 2022.
CCL22 is a macrophage-derived immunosuppressive chemokine that recruits regulatory T cells through the CCL22:CCR4 axis. It was shown to play a key role in suppressing anti-cancer immune responses in different cancer types. The chemokine CCL22, predominately produced by dendritic cells (DCs), regulates T reg migration via binding to its receptor CCR4. CCL22 controls T cell immunity, both by recruiting T regs to the tumor tissue and by promoting the formation of DC-T reg contacts in the lymph node. There was article showed that tumor-associated macrophages (TAMs) produced an abundance of C-C motif chemokine 22 (CCL22), whose expression in the tumor stroma was positively associated with the level of intratumoral phospho-focal adhesion kinase (pFAK Tyr397), tumor metastasis and reduced patient survival.
1μg (R: reducing condition, N: non-reducing condition).